Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | IDH1 | O75874 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | CA9 | Q16790 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | PKLR | P30613 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ly-295501 SCHEMBL29375534 | 1.00 | PKM (0.58) | PKMMAPTIDH1CA2CA9 | |
| SCHEMBL15865555 | 0.90 | IDH1 (0.59) | PKMMAPTIDH1CA2CA9 | |
| SCHEMBL8877626 | 0.89 | PKM (0.70) | PKMMAPTIDH1CA2CA9 | |
| SCHEMBL8879166 | 0.81 | KCNA1 (0.56) | MAPTCA2CA9CA1CA12 | |
| SCHEMBL6425171 | 0.81 | PKM (0.53) | PKMMAPTIDH1PKLRHDAC3 | |
| SCHEMBL8761148 | 0.78 | PKM (0.51) | PKMMAPTCA2CA9CA1 | |
| SCHEMBL5779906 | 0.77 | CCR2 (0.69) | PKMMAPTIDH1CA2CA9 | |
| SCHEMBL9486556 | 0.77 | MEN1 (0.67) | MAPTCA2CA9CA1CA12 | |
| SCHEMBL9476125 | 0.76 | EPHX1 (0.47) | MAPTCA2CA9CA1CA12 | |
| SCHEMBL7993384 | 0.76 | KCNA1 (0.51) | PKMMAPTEPHX1EPHX2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1639 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2805945-B1 | Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors | MSD ITALIA SRL (IT) | 2019-04-03 | — | — | EP | claimed |
| US-20140301976-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. | 2014-10-09 | — | — | US | claimed |
| US-8779171-B2 | Hydroxamates as therapeutic agents | PHARMACYCLICS, INC. (US) | 2014-07-15 | — | — | US | claimed |
| US-20130142758-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. (US) | 2013-06-06 | — | — | US | claimed |
| US-20100291592-A1 | NOVEL MARKER FOR SENSITIVITY AGAINST SULFONAMIDE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-11-18 | — | — | US | claimed |
| US-20090047365-A1 | Novel Concomitant Use of Sulfonamide Compound with Anti-Cancer Agent | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-02-19 | — | — | US | claimed |
| US-20090047278-A1 | Novel Combinational Use of Sulfonamide Compound | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-02-19 | — | — | US | claimed |
| EP-2015070-A1 | NOVEL MARKER FOR SENSITIVITY AGAINST SULFONAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2009-01-14 | — | — | EP | claimed |
| US-20080286282-A1 | Novel Use of Sulfonamide Compound in Combination with Angiogenesis Inhibitor | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-11-20 | — | — | US | claimed |
| EP-1862179-A1 | NOVEL USE OF SULFONAMIDE COMPOUND IN COMBINATION WITH ANGIOGENESIS INHIBITOR | Eisai R&D Management Co., Ltd. (JP) | 2007-12-05 | — | — | EP | claimed |
| EP-1859793-A1 | NOVEL COMBINATIONAL USE OF SULFONAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-11-28 | — | — | EP | claimed |
| EP-1859797-A1 | NOVEL CONCOMITANT USE OF SULFONAMIDE COMPOUND WITH ANTI-CANCER AGENT | Eisai R&D Management Co., Ltd. (JP) | 2007-11-28 | — | — | EP | claimed |
| EP-1797877-A1 | JOINT USE OF SULFONAMIDE BASED COMPOUND WITH ANGIOGENESIS INHIBITOR | Eisai Co., Ltd. (JP) | 2007-06-20 | — | — | EP | claimed |
| US-20060135486-A1 | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors | EISAI CO., LTD. (JP) | 2006-06-22 | — | — | US | claimed |
| EP-0583960-B1 | Synthesis of bicyclic aromatic sulfonic acids, sulfonyl chlorides and sulfonamides | LILLY CO ELI (US) | 1997-05-21 | — | — | EP | claimed |
| EP-0583960-A2 | Synthesis of bicyclic aromatic sulfonic acids, sulfonyl chlorides and sulfonamides | ELI LILLY AND COMPANY (US) | 1994-02-23 | — | — | EP | claimed |
| US-20260132164-A1 | PNU ANTHRACYCLINE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4076459-B1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-0555036-A2 | Antitumor compositions and methods of treatment | ELI LILLY AND COMPANY (US) | 1993-08-11 | — | — | EP | disclosed |
| EP-0555036-A2 | Antitumor compositions and methods of treatment | ELI LILLY AND COMPANY (US) | 1993-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047278-A1 | Novel Combinational Use of Sulfonamide Compound | EGFR, KIT, ERBB2 | PKM 2667/4885MAPT 4340/4885IDH1 3433/4885 |
| US-20060135486-A1 | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors | FLT4, KDR, FLT1 | PKM 3395/4885MAPT 3475/4885IDH1 513/4885 |
| US-20130142758-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | HDAC1, HDAC3, HDAC5 | PKM 3513/4885MAPT 4192/4885IDH1 129/4885 |
| US-20140301976-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | HDAC1, HDAC3, HDAC5 | PKM 3513/4885MAPT 4192/4885IDH1 129/4885 |
| US-20090047365-A1 | Novel Concomitant Use of Sulfonamide Compound with Anti-Cancer Agent | TOP1, TOP2A, TOP2B | PKM 1903/4885MAPT 789/4885IDH1 782/4885 |
| US-20260132164-A1 | PNU ANTHRACYCLINE DERIVATIVES AND METHODS OF USE THEREOF | TOP1, NCL, NOLC1 | PKM 3662/4885MAPT 4774/4885IDH1 122/4885 |
| US-20080286282-A1 | Novel Use of Sulfonamide Compound in Combination with Angiogenesis Inhibitor | KDR, FLT4, FLT1 | PKM 2169/4885MAPT 3691/4885IDH1 1233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.